![Mark Opler staff image](https://www.wcgclinical.com/wp-content/uploads/2018/05/Mark-Opler_new-300x300.png)
Mark A. Opler, PhD, MPH
Chief Research Officer
Biography
Dr. Opler joined WCG in 2017 as Chief Research Officer at MedAvante-ProPhase. In this role, he directs scientific research and development and leads ongoing studies in psychiatry, neurodevelopment, and other areas of neuroscience.
Dr. Opler has served as a faculty member in the Departments of Psychiatry and Environmental Medicine at New York University School of Medicine and in the Department of Neuroscience at Columbia University, College of Physicians and Surgeons. His academic research focuses on the etiology, phenomenology, and treatment of serious and persistent mental disorders. He is a co-author and developer of several clinical assessment tools, including the SNAPSI, CGI-DS, and NY-AACENT. He is also a contributor to the latest edition of the PANSS Manual©.
Dr. Opler has received research support from the US NIMH, the Brain & Behavior Foundation (formerly NARSAD), the Stanley Medical Research Institute, and the Qatar National Research Fund. He has co-authored more than 50 peer-reviewed publications and has contributed to multiple book chapters and review articles on clinical assessment, research methodology, and mental health.
He received his PhD and MPH from Columbia University and his BSc from SUNY at Stony Brook. He is a graduate of the Psychiatric Epidemiology Training Program at Columbia University and completed his postdoctoral fellowship at the New York State Psychiatric Institute.
Latest insights by Mark
![](https://www.wcgclinical.com/wp-content/uploads/2024/12/oncCoverInsight3.png)
The Next Wave of Innovation: Silence Speaks Volumes in Clinical Research
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2023/12/trendsAndInsightsPhoto1.png)
Past Promises, the Future Hope of Neuroscience Clinical Research
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2023/06/brandStock22.gif)
RAADs Call into Question the Utility of Existing Depression Scales. Now What?
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/on-the-future-of-depression-trials-part-3-of-wcgs-transforming-cns-trials-series.png)
On the Future of Depression Trials: Part 3 of WCG’s Transforming CNS Trials Series
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/on-the-future-of-schizophrenia-trials-part-2-of-wcg-s-transforming-cns-trials-series.png)
On the Future of Schizophrenia Trials: Part 2 of WCG’s Transforming CNS Trials Series
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/on-the-future-of-psychiatric-disorders-transforming-cns-trials.png)
On the Future of Psychiatric Disorders: Part 1 of WCG’s Transforming CNS Trials Series
Podcasts![WCG Insights](https://www.wcgclinical.com/wp-content/themes/wcg/dist/images/default-insights-image.jpg)
Meeting of the Minds: Exploring New and Old Worldviews on Depression
Blog Posts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/clinical-trials-in-autism-and-neurodevelopmental-disorders-dr-scott-hunter.png?v=1697042815)
The State of Clinical Trials in Autism and Neurodevelopmental Disorders with Dr. Scott Hunter
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/exciting-developments-in-psychopharmacology-with-guest-andrew-cutler-md.png)
Podcast: Exciting Developments in Psychopharmacology with guest Andrew Cutler, MD
Podcasts![](https://www.wcgclinical.com/wp-content/uploads/2022/03/the-most-pressing-challenges-and-opportunities-in-pain-research-with-guest-nathaniel-katz-md-ms.png)